Retail Sales Assistant/Sleep Coach

Casual Position:3–5 days per week
1–2 Saturday shifts per month required
Located in Newcastle, NSW
Take your first step into the healthcare industry – full training provided

About the Business

At ResMed, we pioneer innovative solutions that help people live healthier, higher-quality lives by treating and managing sleep apnoea, COPD and other chronic conditions. Our cloud-connected medical devices and out-of-hospital software platforms empower patients, healthcare professionals and caregivers across more than 120 countries to deliver care where it matters most — at home.

We're passionate about creating a supportive and inclusive work environment and are looking for people who bring positivity, empathy and a strong customer-first mindset to everything they do.

About the Role

As a Sleep Coach, you will be the face of ResMed in our Newcastle retail clinic. Your mission is to create an outstanding customer experience while driving sales and supporting people on their sleep health journey.

You will work collaboratively as part of a team to deliver exceptional customer service, maintain high retail standards, and contribute to business growth while helping customers achieve the best possible therapy outcomes.

This is an exciting opportunity for someone who enjoys building relationships, achieving sales goals and making a genuine difference in people's lives.

No healthcare experience is required — comprehensive training is provided.

Key Responsibilities

Deliver exceptional customer service by greeting customers, understanding their needs and providing tailored sleep therapy solutions.
Respond to customer enquiries in-store and over the phone.
Achieve individual and clinic sales targets through effective product and service recommendations.
Investigate and help customers problem-solve therapy and equipment issues.
Provide equipment set-up, ongoing support and education to encourage successful therapy outcomes.
Fit customers for masks and recommend the most suitable options based on training.
Educate customers on the safe and effective use of sleep therapy equipment.
Conduct customer follow-up calls to support therapy compliance, discuss trial outcomes and build long-term customer relationships.
Maintain visual merchandising standards and ensure the clinic is presented to a high standard at all times.
Manage stock levels, inventory control and replenishment.
Process Point of Sale (POS) transactions, cash handling and daily administrative duties.
Maintain, prepare and check trial devices and equipment to ensure they are customer-ready.
Complete ongoing product and therapy training to maintain expert product knowledge.

Your Day-to-Day

Create amazing customer experiences — greet, listen and guide customers to the right solutions.
Drive sales success by achieving targets and contributing to clinic growth.
Keep the store looking its best through merchandising, stock control and presentation.
Stay ahead of the game by completing product training and sharing your knowledge with customers and colleagues.
Follow up with customers to build trust, loyalty and positive therapy outcomes.
Handle POS transactions and administration accurately and efficiently.
Ensure trial equipment is maintained, checked and ready for customer use.

About You

To be successful in this role, you'll bring:

Retail, sales or customer service experience (2+ years preferred).
A sales-focused mindset and a passion for achieving goals.
Strong communication skills with the ability to build rapport and adapt your approach to different customers.
A warm, caring and customer-focused attitude.
Excellent problem-solving and active listening skills.
Strong attention to detail across administration, reporting and store presentation.
Confidence using technology and POS systems.
Experience with Salesforce or Shopify is highly regarded.
A strong work ethic, reliability and honesty.
The ability to work independently and collaboratively as part of a team.
Flexibility to work a rotating roster including weekdays, weekends and public holidays as required.
Availability to work 3–5 days per week, including 1–2 Saturdays per month.

Healthcare, pharmacy or healthcare retail experience is advantageous but not essential. We're looking for people with a positive attitude, strong customer focus and a genuine willingness to learn.

Why Join ResMed?

Full training provided — become a sleep health expert.
Meaningful work — make a real difference to people's lives every day.
Career growth opportunities with a global leader in healthcare technology.
Supportive and inclusive team culture that values your ideas and contributions.
Employee benefits, including an Employee Assistance Program to support your mental fitness and wellbeing.
Exposure to an innovative and growing industry focused on improving health outcomes.

If you're enthusiastic, motivated and excited by the opportunity to build a career that combines retail, customer service and healthcare, we'd love to hear from you.

Apply now and help improve lives — one good night's sleep at a time.

Joining us is more than saying “yes” to making the world a healthier place. It’s discovering a career that’s challenging, supportive and inspiring. Where a culture driven by excellence helps you not only meet your goals, but also create new ones. We focus on creating a diverse and inclusive culture, encouraging individual expression in the workplace and thrive on the innovative ideas this generates. If this sounds like the workplace for you, apply now! We commit to respond to every applicant.

About the company

ResMed creates cloud-connected medical devices and software platforms to treat and manage sleep apnea, COPD, and other chronic diseases. Its devices (like sleep therapy gear) collect patient data and deliver therapy, while connected software platforms enable remote monitoring, coaching, and caregiver support. The company sells medical devices and offers software subscriptions, generating revenue from product sales and ongoing service fees. Unlike some competitors, ResMed combines hardware with cloud-based analytics and a broad ecosystem that supports patients, healthcare professionals, and caregivers across more than 120 countries. Its goal is to improve patient care and quality of life while reducing hospital visits and overall healthcare costs.

Company Size

5,001-10,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1989

Get referred to Resmed

See people who can refer or advise you

Simplify's Take

What believers are saying

September 2026 guidance shows 5%-7% revenue growth and 12%-14% core EPS growth.
MatrixCare closed September 1, 2026, freeing capital for higher-margin core businesses.
ResMed's connected network and Oura partnership expand diagnosis and PAP adoption funnels.

What critics are saying

Astral no-new-sales in fiscal 2027 removes $75 million revenue and damages trust.
KPMG exit and PwC onboarding increase reporting disruption risk before the next 10-Q.
Philips Respironics' U.S. return in 2027 can compress pricing and share quickly.

What makes Resmed unique

ResMed's cloud-connected AirSense platform locks in recurring resupply and adherence data.
Noctrix acquisition broadens ResMed beyond apnea into restless legs syndrome treatments.
MatrixCare sale and core-device focus sharpen execution around sleep, breathing, and home care.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Unlimited Paid Time Off
Paid Vacation
Paid Holidays
Parental Leave
401(k) Retirement Plan
Employee Assistance Program (EAP)

Growth & Insights and Company News

6 month growth

1 year growth

2 year growth

Yahoo Finance

Oct 30th, 2026

ResMed Q1 revenue rises 7% to $1.4B, EPS up 14%, with record $1B returned to shareholders

ResMed reported first-quarter fiscal 2027 revenue of $1.4 billion, up 6% reported and 7% on a core constant currency basis. Non-GAAP earnings per share rose 14% to $2.91, and gross margin gained 50 basis points to 62.5%. The sleep apnoea device maker returned more than $1 billion to shareholders through dividends and buybacks, a record. Buybacks alone totalled $936 million. Free cash flow fell to $374 million on higher inventory and cash tax prepaids. Life support device revenue dropped 94% in the Americas and 79% in the rest of the world after a field safety action on its Astral device. ResMed took a $42 million reserve. It kept full-year guidance: revenue of $5.75 billion to $5.85 billion and non-GAAP EPS of $12 to $12.25.

Business Insider

Oct 29th, 2026

Ozlo raises $22M Series B led by Modi Ventures as sleepbuds hit 260,000 customers

Sleep technology company Ozlo has raised $22 million in Series B funding led by Modi Ventures. The round includes previously issued convertible instruments, and existing investors such as LifeArc, Artis Ventures, and Resmed took part. The Boston-based maker of Ozlo Sleepbuds has passed 260,000 customers in under two years. It will use the money to grow globally, invest in hardware, software, and research, and move beyond earbuds into broader sleep and nighttime health. That includes regulatory work to submit a tinnitus product to the US Food and Drug Administration for review. Ozlo also partners with Dreem Health, a virtual sleep clinic, to connect users with sleep specialists. In July 2026, it launched Sleepbuds 2, with up to 14 hours of battery life.

Yahoo Finance

Oct 28th, 2026

ResMed Q3 earnings preview: analysts expect 4.2% revenue growth as shares rise 12.9%

ResMed (NYSE:RMD) reports third-quarter results this Thursday after market close. Analysts expect revenue to grow 4.2% year on year, down from 9.1% in the same quarter last year. Last quarter, the medical device company met revenue expectations with $1.46 billion, up 8.6%, and beat analysts' earnings per share estimates. It has missed Wall Street's revenue estimates several times over the past two years. Analysts have mostly held their estimates over the last 30 days. ResMed shares are up 12.9% in the past month, against an average 3.6% gain for healthcare equipment and supplies stocks. The average analyst price target is $251.52, compared with a share price of $250.83.

The Motley Fool Australia

Oct 28th, 2026

Are ResMed shares a strong buy before its results on Friday?

Are ResMed shares a strong buy before its results on Friday? Here's my verdict on whether I'd buy shares before the announcement. Published October 28, 12:05 pm AEDT ResMed Inc (ASX: RMD) shares haven't had the easiest 12 months. The sleep health giant's shares are trading around $35.50 on Wednesday, leaving them approximately 10% lower than this time last year. And with the company set to report its first-quarter FY27 results on Friday, investors will soon have another opportunity to see how the business is performing. So, could now be a good time to buy? Here's what I think. What should investors expect on Friday? Analysts are expecting a relatively modest start to the financial year. Revenue is forecast to increase approximately 4% to US$1.39 billion, with adjusted earnings expected to improve by around 5.5%. That would represent slower sales growth than ResMed delivered last financial year, when revenue increased 10%. But I think there's a good reason to look beyond the overall sales figure. ResMed has sold its MatrixCare software business, while sales of its Astral ventilators have been suspended following a safety issue. These developments could weigh on its reported growth. What I'll be most interested in is whether demand for its sleep apnoea treatments remains strong. Analysts expect ResMed's sleep and breathing health business to deliver revenue growth of around 6% for the quarter. I think that would be an encouraging result, especially as the company continues working to reach more patients. I'll also be watching profitability. Higher freight and component costs have created some challenges, but ResMed has a strong record of managing its expenses while growing. If that continues, I think shareholders will have plenty to be pleased about. Why I remain optimistic. The biggest reason I like ResMed shares is the sheer number of people who could benefit from its products. Sleep apnoea affects hundreds of millions of people worldwide, yet many don't even know they have it. According to ResMed's estimates, fewer than 20% of people with the condition in the United States have been diagnosed or treated. And the situation is even worse in many other countries. I think that gives ResMed a huge opportunity to grow over the coming decades. The company is investing in technologies that make sleep apnoea easier to diagnose, including home testing solutions that could help people access treatment sooner. As awareness improves and more patients seek help, I expect demand for its devices to increase. Management is aiming for high-single-digit annual revenue growth over the coming years, with earnings growing even faster. I think that's an encouraging ambition for a company with so much room to expand. Are ResMed shares good value? At $35.50, ResMed shares are trading on a PE ratio of approximately 21 times forecast FY27 earnings and 19 times FY28 estimates. I think that's a reasonable valuation for a global healthcare leader with strong profitability and considerable growth potential. There are challenges to consider, including competition from new sleep apnoea treatments and the need to keep developing better products. But I believe ResMed is well-placed to continue expanding its business as more people receive diagnoses and treatment. And at this valuation, I think investors are getting an opportunity to buy a strong business at a sensible price. Foolish takeaway. I would be happy buying ResMed shares before Friday's announcement. The results could bring some volatility, especially if earnings fall short of expectations. But I'm much more interested in where ResMed could be in five or ten years. With millions of potential patients still waiting to be diagnosed and treated, I think the company has an enormous opportunity ahead. And at around 19 times FY28 earnings, I'd be comfortable buying shares today and giving ResMed plenty of time to grow.

Yahoo Finance

Oct 23rd, 2026

ResMed launches AirTouch F40 mask in US, but analysts see only an incremental boost

ResMed has launched its AirTouch F40 CPAP mask in the US. The fabric-cushioned design connects to the company's myAir and AirView platforms and aims to improve comfort, adherence and fitting for obstructive sleep apnea patients. Existing AirFit F40 users can switch to the new ComfiSoft fabric cushion without a full refit. This could lift resupply activity and keep patients within ResMed's connected ecosystem. The launch looks incremental. Supply chain costs and the Astral ventilator remediation remain the main near-term risks, with a headwind expected in FY2027. From July to September 2026, ResMed retired 972,000 shares for $200 million. Analysts' narrative projects $6.6 billion in revenue and $1.9 billion in earnings by 2029.

Resmed

Retail Sales Assistant

About the job